Acute Limb Ischemia (ALI) occurs when there is a sudden lack of blood flow to a limb, which is often caused by a blood clot. Although treatable, ALI is associated with high amputation rates and mortality if not treated immediately. However, new data from the STRIDE study shows for the […]
Other News
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on May 1, 2023 that were approved by the Compensation Committee of its Board of […]
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
— Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives — — Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing — — International Strategy Progressing with CSL Seqirus Partnership for Australia […]
Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation
– Transaction values Avertix at an enterprise value of $195 million – Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events, including silent heart attacks EATONTOWN, N.J. and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) — Avertix Medical, Inc. (“Avertix” or […]
Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key […]
CytoSorbents Reports First Quarter 2023 Results
Pivotal U.S. and Canada STAR-T Trial enrollment enters the last third of the study. Strong customer demand from Q4 2022 continued into Q1 2023, with current expectation of overall sales growth in 2023 PRINCETON, N.J., May 02, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening […]
Thubrikar Aortic Valve to Present Promising Initial Results of CE Mark-Enabling Study With Novel Optimum TAV™ at EuroPCR 2023
NORRISTOWN, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc., is happy to announce that results of the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV™) in patients with severe aortic stenosis will be presented at the upcoming EuroPCR 2023 Conference. EuroPCR is an annual, world-leading conference on interventional cardiovascular […]
US Heart & Vascular and Rubicon Founders Announce Partnership to Build the Premier Cardiovascular Value-Based Care Model in the United States
Partnership Reinforces USHV’s Position as a Leading Cardiovascular Practice Management Organization and Will Drive Efforts to Transform How Quality Cardiovascular Care Is Delivered NASHVILLE, Tenn.–(BUSINESS WIRE)–US Heart & Vascular (“USHV”), a leading national provider of support services to cardiovascular physician practices, announced today that it has entered into an agreement […]
HeartBeam Completes $25 Million Capital Raise and Updates 2023 Strategic Focus and Financial Guidance
HeartBeam to Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Funding to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones, Extends Cash Runway into Late 2024 HeartBeam to Host Conference Call to Discuss Financing, Strategic Initiatives and First Quarter 2023 […]
Valbiotis – Combined Annual Shareholders General Meeting held on May 2, 2023
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its Combined Annual Shareholders Meeting was held on May 2, 2023 at Espace Encan, La Rochelle, under […]



